The AHA today submitted comments to House leaders on the Lower Drug Costs Now Act (H.R. 3), legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.
 
“H.R. 3 offers several solutions that will help hold drug manufacturers accountable,” AHA said. “Specifically, we commend your work to reform the Medicare Part D Prescription Drug Program by eliminating the coverage gap, capping out-of-pocket costs for beneficiaries and placing more responsibility on both health insurers and drug manufacturers — directly benefiting consumers at the pharmacy counter.” AHA also praised the inclusion of mandatory inflationary rebates for both Medicare Part B and Part D drugs and said it “makes sense to allow Medicare to negotiate directly with drug manufacturers on the price of drugs.”
 
However, AHA also expressed concern with language in the legislation that would allow the commercial market access to the Health and Human Services-negotiated price. “Specifically, the AHA does not support government-rate setting in the commercial market,” the association said. “Instead, we encourage Congress to focus on ways to balance incentives for innovation with provisions that allow for more fair pricing and negotiations.” Specifically, AHA said it supports provisions “that would provide hospitals and other purchasers with more information about drug development costs to help them negotiate prices with drug manufacturers, as well as provisions that would resolve anti-competitive issues that have allowed drug manufacturers to extend patents and market exclusivity periods beyond what was envisioned to incentivize innovation.”
 
The House Ways and Means Committee, Energy and Commerce Committee, and Education and Labor Committee each approved similar versions of the bill. The bills must be reconciled before they go to the House floor for a vote, which will likely be next month.

Related News Articles

Headline
The AHA April 30 released a report highlighting how hospitals and health systems continue to experience significant financial headwinds that can challenge…
Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Perspective
Public
One year ago, a nurse at Children’s Hospital Colorado went above and beyond in a way that a very young patient and her family will never forget. Kayla…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…